Overview

XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma

Status:
Not yet recruiting

Trial end date:
2027-02-01

Target enrollment:

Participant gender:

Summary

This is an open label, randomized, phase Ⅱ, multi-cohort study to treat subjects with ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma. The patients will be randomized into two arms consist of Penpulimab + Anlotinib (3 weeks/cycle) + XELOX and XELOX at a ratio of 1:1. This study is conducted to assess safety and anti-tumor activity of the monoclonal antibody Penpulimab in combination with Anlotinib and standard chemotherapy as adjuvant treatment for ctDNA-positive Gastric, or Gastroesophageal Junction Carcinoma.

Phase:

Phase 2

Details

Lead Sponsor:

The First Affiliated Hospital with Nanjing Medical University

Collaborator:

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Treatments:

Capecitabine
Oxaliplatin